SRR1797255
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 63
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.300
- DNA_REPAIR+0.220
- SPERMATOGENESIS+0.180
- E2F_TARGETS+0.150
- MYC_TARGETS_V2+0.140
- G2M_CHECKPOINT+0.090
- MYC_TARGETS_V1+0.090
- HEME_METABOLISM+0.050
- OXIDATIVE_PHOSPHORYLATION+0.050
- MITOTIC_SPINDLE+0.030
Top 10 suppressed
- ANGIOGENESIS-0.430
- ALLOGRAFT_REJECTION-0.420
- INTERFERON_GAMMA_RESPONSE-0.420
- COAGULATION-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- INFLAMMATORY_RESPONSE-0.390
- INTERFERON_ALPHA_RESPONSE-0.390
- IL2_STAT5_SIGNALING-0.360
- IL6_JAK_STAT3_SIGNALING-0.350
- KRAS_SIGNALING_UP-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_9M5XJ10G | medulloblastoma | — | 0.936 |
| 2 | BS_ERWT0ZWE | medulloblastoma | — | 0.932 |
| 3 | BS_V9HVBBDW | medulloblastoma | — | 0.931 |
| 4 | BS_GE2RVZE6 | medulloblastoma | — | 0.927 |
| 5 | BS_61E80SD6 | medulloblastoma | — | 0.922 |
| 6 | TCGA-E2-A105-01A-11R-A10J-07 | — | B | 0.921 |
| 7 | BS_E3BAT4C1 | medulloblastoma | — | 0.915 |
| 8 | BS_W9AT0MR7 | medulloblastoma | — | 0.915 |
| 9 | BS_J8G4SH4Z | medulloblastoma | — | 0.915 |
| 10 | BS_HD4EJYE3 | medulloblastoma | — | 0.914 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.090 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.050 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.020 | Inavolisib | — uncovered |